

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

07 Jul 2026

### Investigating the effect of contrast agent reduction and lowering radiation dose on the image quality of pulmonary Computed Tomography (CT) in patients suspected of pulmonary thromboembolism using iterative reconstruction

#### Protocol summary

##### Study aim

To determine the effect of the contrast agent and radiation dose reduction, on the image quality of the pulmonary Computed Tomography Angio (CTA) in patients suspected of pulmonary thromboembolism

##### Design

This study is a randomized clinical trial containing 40 samples. This double-blind study has two parallel groups (control or standard dose and intervention or reduced dose). A table of random numbers will be used to allocate samples to control and intervention groups randomly.

##### Settings and conduct

In this randomized clinical trial inpatients suspected of pulmonary embolism, at Shahid Faghihi hospital, Shiraz will be allocated into control (standard protocol) and intervention groups. The image quality of pulmonary CTA of both groups will be evaluated by two radiologists blinded to the scanning parameters.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients suspected of thromboembolism on the basis of clinical indications, Abnormal level of plasma D-dimer, having deep veins thrombosis of lower limb Exclusion criteria: creatinine > 1.36 mg/dL, allergy to iodinated contrast, severe pneumonia and atelectasis, Confirmed pregnancy or suspicious of pregnancy, Body Mass Index > 30 kg/m<sup>2</sup>, Critically ill patient or hospitalized in ICU, age < 18 years

##### Intervention groups

Control group: patients will be scanned by a standard protocol containing a 1 ml/kg contrast agent and 120 kVp. Intervention group: patients will be scanned with a 0.5 ml/kg contrast agent and 100kVp. CT images will be reconstructed by Iterative algorithm (IR) in both control and intervention groups.

##### Main outcome variables

Independent variables: Contrast agent and radiation dose. Dependent variable: image quality of pulmonary CT angiography

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220313054273N1**

Registration date: **2022-08-19, 1401/05/28**

Registration timing: **prospective**

Last update: **2022-08-19, 1401/05/28**

Update count: **0**

##### Registration date

2022-08-19, 1401/05/28

##### Registrant information

##### Name

Rezvan Ravanfar Haghghi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 71 3628 1464

##### Email address

sravanfarr@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-08-23, 1401/06/01

##### Expected recruitment end date

2023-06-21, 1402/03/31

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Investigating the effect of contrast agent reduction and lowering radiation dose on the image quality of pulmonary Computed Tomography (CT) in patients suspected of pulmonary thromboembolism using iterative reconstruction

**Public title**

The effect of contrast agent reduction and low dose radiation on image quality in Pulmonary CT angiography

**Purpose**

Diagnostic

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients who are suspicious of pulmonary emboly on the basis of clinical indication Abnormal level of plasma D-dimer Having deep veins thrombosis of lower limb age > 18 years BMI less than 30kg/m2 GFR greater than 60ml/min/1.73m2 Creatinine less than 1.3mg/ml Willingness to participate in the study and sign informed consent Does not have allergy to iodine contrast

**Exclusion criteria:**

Patient with severe pneumonia and atelectasis Confirmed pregnancy or suspicious of pregnancy Critically ill patient or hospitalized in ICU

**Age**

From **18 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

- Participant
- Outcome assessor

**Sample size**

Target sample size: **40**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

This study will be done by simple randomization. The unit of randomization is individual. The table of random numbers that will be used in this study contains a series of numbers, zero and one, produced by the random method. In this study, the table of random numbers will be used to make the sequence random. Zero and one numbers will be allocated to the control (standard pulmonary CT Angio) and intervention (contrast agent reduction and low dose of radiation) groups, respectively. This process will continue until the end of the sampling process so that finally 20 patients will be assigned to each group.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In this study, the investigator (radiologists who evaluate the quality of pulmonary CTA) and patients (ready to take part in this study and signed consent form) are not aware of the scanning protocol. They are blind to the amount of contrast agent and radiation dose. Technologists responsible for scanning patients and the student responsible for performing the study are aware of the scanning protocol.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Shiraz University of Medical Sciences

**Street address**

Research Center, 8th Floor, Mohammad Rasolallah Research Tower, Khalili street

**City**

Shiraz

**Province**

Fars

**Postal code**

7193635899

**Approval date**

2022-06-21, 1401/03/31

**Ethics committee reference number**

IR.SUMS.MED.REC.1400.455

**Health conditions studied****1****Description of health condition studied**

Pulmonary thromboembolism

**ICD-10 code**

I26

**ICD-10 code description**

Pulmonary embolism

**Primary outcomes****1****Description**

The objective image quality of pulmonary CT Angio will be determined by radiologists through a scoring system. The quantitative image quality will be determined by quantitative parameters such as Signal-to-Noise Ratio. The quantity of radiation dose to the patient will be measured by the CT system. The related values will be

shown on the Dose Report Page available at the end of the image series.

#### **Timepoint**

The CT images will be sent to Picture Archiving and Communication System immediately after the scanning procedure completed. Then the qualitative and quantitative evaluation of the image quality of pulmonary CT Angio will perform. The results of the dose measurement will be available immediately after completing the scan.

#### **Method of measurement**

Quantitative pulmonary Computed Tomography Angio (CTA) image quality will be measured by Signal-to-Noise Ratio (SNR). SNR results from the division of the mean CT density of the main pulmonary arteries (left and right) filled with contrast agent by the standard deviation of the background region (without contrast agent for example muscles surrounding the scapula). Qualitative pulmonary CT angiography is measured by the scores which are devoted to each series of images. Qualitative pulmonary CT angiography image quality will be measured by visual assessment. In this method the radiologist will use a scoring system on the basis of 5 scale scores as follow, (1) undiagnosable pulmonary CTA image (2) limited diagnostic value (3) sufficient diagnostic value (4) good image quality (5) excellent diagnostic value. Radiation dose to the patient will be measured by CT dose indices which are available on the page of dose report at the end of the CT image series.

#### **Secondary outcomes**

empty

#### **Intervention groups**

##### **1**

#### **Description**

Intervention group: Patients suspected of pulmonary embolism referred to Shahid Faghihi Hospital (Shiraz) will be scanned by contrast agent reduction and radiation dose reduction protocol. The amount of injected contrast agent to the patients in intervention group will be 0.5 millilitre per each kilogram of body weight. The Pecnograph contains 300mg/ml (milligram iodine per millilitre) made in Iran is the available contrast agent. This contrast agent will be used to scan patients in intervention group. These patients will be scanned by 128-MDCT Philips Ingenuity system, made in Netherland, at 100kVp. This CT system uses Iterative Reconstruction (IR) algorithm to reconstruct CT images. The pulmonary CT Angio images of patients in intervention group will be reconstructed by iDose level4 (a type of IR reconstruction), made in Netherland by Philips Company.

#### **Category**

Diagnosis

##### **2**

#### **Description**

Control group: Patients suspected of pulmonary embolism referred to Shahid Faghihi Hospital (Shiraz) will

be scanned by standard protocol (pulmonary CT Angio). The amount of injected contrast agent to the patients in control group will be 1.0 millilitre per each kilogram of patient's body weight. The Pecnograph contains 300mg/ml (milligram iodine per millilitre) made in Iran is the available contrast agent. This contrast agent will be used to scan patients in control group. The patients in control group will be scanned by 128-MDCT Philips Ingenuity system, made in Netherland, at 100kVp. This CT system uses Iterative Reconstruction (IR) algorithm to reconstruct CT images. The pulmonary CT Angio images of patients in control group will be reconstructed by iDose level4 (a type of IR reconstruction), made in Netherland by Philips Company.

#### **Category**

Diagnosis

#### **Recruitment centers**

##### **1**

#### **Recruitment center**

##### **Name of recruitment center**

Shahid Faghihi Hospital

##### **Full name of responsible person**

Fariba Zarei

##### **Street address**

ZAND Ave, Shiraz University of Medical Sciences

##### **City**

Shiraz

##### **Province**

Fars

##### **Postal code**

7134814336

##### **Phone**

+98 71 3628 1464

##### **Fax**

+98 71 3628 1506

##### **Email**

zareifari@gmail.com

#### **Sponsors / Funding sources**

##### **1**

#### **Sponsor**

##### **Name of organization / entity**

Shiraz University of Medical Sciences

##### **Full name of responsible person**

Mahtab Memarpour

##### **Street address**

Shiraz University of Medical Sciences

##### **City**

Shiraz

##### **Province**

Fars

##### **Postal code**

7134814336

##### **Phone**

+98 71 3628 1464

##### **Email**

sravanfarr@gmail.com

**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Shiraz University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Shiraz University of Medical Sciences  
**Full name of responsible person**  
Rezvan Ravanfar Haghighi  
**Position**  
Assistant professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Medical Physics  
**Street address**  
Medical Imaging Research Centre, 8th Floor,  
Mohammad Rasolallah Research Tower, Khalili street  
**City**  
Shiraz  
**Province**  
Fars  
**Postal code**  
7193635899  
**Phone**  
+98 71 3628 1464  
**Email**  
sravanfarr@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Shiraz University of Medical Sciences  
**Full name of responsible person**  
Rezvan Ravanfar Haghighi  
**Position**  
Assistant professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Medical Physics  
**Street address**  
Medical Imaging Research Centre, 8th Floor,

Mohammad Rasolallah Research Tower, Khalili street  
**City**  
Shiraz  
**Province**  
Fars  
**Postal code**  
7193635899  
**Phone**  
+98 71 3628 1464  
**Email**  
sravanfarr@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Shiraz University of Medical Sciences  
**Full name of responsible person**  
Rezvan Ravanfar Haghighi  
**Position**  
Assistant Professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Medical Physics  
**Street address**  
Medical Imaging Research Center, 8th Floor,  
Mohammad Rasollallah Research Tower, Khalili  
Street, Shiraz, Iran  
**City**  
Shiraz  
**Province**  
Fars  
**Postal code**  
7193635899  
**Phone**  
+98 71 3628 1464  
**Fax**  
+98 71 3628 1506  
**Email**  
sravanfarr@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Not applicable

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to

make this available

**Title and more details about the data/document**

Part of the data can be shared after unidentified.

**When the data will become available and for how long**

3 months after publication

**To whom data/document is available**

Interested researchers in this field

**Under which criteria data/document could be used**

using for research work

**From where data/document is obtainable**

Research and technology deputy

**What processes are involved for a request to access data/document**

Sending an Email to the research and technology deputy  
Shiraz University of Medical Sciences

**Comments**